More Videos
SPECIAL REPORT
MOST SHARED
- Kuoni CEO Sees Recovery in Travel Sector
- US Markets Bracing for Selloff On Worries About Dubai's Debt
- No Thanksgiving Rest for Retailers in Sales Race
- More Asia Executives Resigned to Economy Flights: Survey
- Attraction of Switzerland to Businesses
- UK's Darling to Downgrade 2009 Growth Forecast
- Oil Falls Toward $73 Amid Dubai Debt Jitters
- 4 Thanksgiving Week Buys For Your Portfolio: Market Pros
- There's a 'Great Chance' For a Double-Dip Recession: Strategist
- Revenge of the Gangsta Nerds
- Will TCU See The "Flutie Effect?"
- Retail Earnings and Sales to Improve in Q4: Analyst
- Consumers Catching the Holiday Spirit
- It's Beginning To Look A Lot More Riskless
- Crescenzi: Claims Level Suggests End to Job Losses
- Hedge Funds Take Early Lead in Warren Buffett's 'Big Bet'
- Dubai Debt Delays Revive Fear of Financial Crisis
- US Markets Bracing for Selloff on Dubai Debt Worries
- US Dollar Falls to 14-Year Low Against the Yen
- ING Prices Share Issue at Hefty Discount
- No Thanksgiving Rest for Retailers in Sales Race
- UK's Darling to Downgrade 2009 Growth Forecast
- Tommy Hilfiger's Estate in Conn. Sells for $20 Million
- Cheap Robotic Hamsters Are Holiday's Unlikely Craze
- Almunia Set to Take Neelie Kroes' EU Competition Job
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
Their findings are published in the Annals of Internal Medicine and touted and brought to my attention in an email from a GlaxoSmithKline [GSK
Loading...
()
] PR person. A meta-analysis is what one of our contacts called "a mish-mash" of a bunch of clinical trials.
Two doctors from Cedars-Sinai in L.A. did the review. In the publication, Drs. George Diamond and Sanjay Kaul say they have no financial conflicts to disclose. The pair conclude that "the risk for myocardial infarction (heart attack) and death from cardiovascular disease for diabetics taking (Avandia) is uncertain. Neither increased nor decreased risk is established."
An FDA Advisory Committee disagrees voting overwhelmingly last week that Avandia raises the risks of having a heart attack. It is now up to the FDA to decide whether that risk will be put in a so-called "Black Box" on the Avandia label--the agency's harshest safety warning. But the GSK campaign to try to prevent that has clearly begun.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes